Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (Sandostatin)

C. Invitti, M. De Martin, A. Brunani, M. Piolini, F. Cavagnini

Research output: Contribution to journalArticlepeer-review


Three patients with Cushing's disease and one patient with paraneoplastic hypercortisolism were treated for 24-49 days with the long-acting analogue of somatostatin, SMS 201-995, Sandoz (SMS), administered in increasing doses up to 400-1200 μg daily. In the three Cushing's patients during SMS treatment plasma ACTH displayed an initial rise and a subsequent decrease. The pattern of urinary free cortisol (UFC) tended to be opposite to that of ACTH. In one of these patients, UFC continued to decrease throughout the treatment, without becoming normal. In the patient with paraneoplastic hypercortisolism, SMS was associated with a progressive decrease, though not the normalization, of UFC and of ACTH and cortisol levels. The reciprocal changes of the ACTH and UFC levels observed in the three Cushing's patients receiving SMS suggest that the peptide may act temporarily by inhibiting glucocorticoid secretion. In view of the marked reduction of UFC recorded in 1 of the 3 Cushing's patients and in the patients with paraneoplastic Cushing's syndrome, administration of SMS seems worth trying in cases of ACTH-dependent hypercortisolism requiring medical treatment.

Original languageEnglish
Pages (from-to)275-281
Number of pages7
JournalClinical Endocrinology
Issue number3
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (Sandostatin)'. Together they form a unique fingerprint.

Cite this